Compare Cipla with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PFIZER - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PFIZER CIPLA/
PFIZER
 
P/E (TTM) x 28.5 41.6 68.3% View Chart
P/BV x 4.0 6.9 58.2% View Chart
Dividend Yield % 0.5 0.5 102.9%  

Financials

 CIPLA   PFIZER
EQUITY SHARE DATA
    CIPLA
Mar-20
PFIZER
Mar-19
CIPLA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs5863,840 15.2%   
Low Rs3572,080 17.2%   
Sales per share (Unadj.) Rs207.0455.0 45.5%  
Earnings per share (Unadj.) Rs18.693.8 19.8%  
Cash flow per share (Unadj.) Rs33.2109.4 30.3%  
Dividends per share (Unadj.) Rs4.0022.50 17.8%  
Dividend yield (eoy) %0.80.8 111.7%  
Book value per share (Unadj.) Rs195.5658.2 29.7%  
Shares outstanding (eoy) m806.3545.75 1,762.5%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.36.5 35.0%   
Avg P/E ratio x25.331.6 80.3%  
P/CF ratio (eoy) x14.227.1 52.5%  
Price / Book Value ratio x2.44.5 53.6%  
Dividend payout %21.524.0 89.7%   
Avg Mkt Cap Rs m379,912135,420 280.5%   
No. of employees `00025.82.6 982.3%   
Total wages/salary Rs m30,2703,238 934.7%   
Avg. sales/employee Rs Th6,459.67,911.4 81.6%   
Avg. wages/employee Rs Th1,171.21,230.9 95.2%   
Avg. net profit/employee Rs Th580.21,630.7 35.6%   
INCOME DATA
Net Sales Rs m166,94920,815 802.1%  
Other income Rs m3,4421,674 205.6%   
Total revenues Rs m170,39122,489 757.7%   
Gross profit Rs m32,0605,712 561.3%  
Depreciation Rs m11,747714 1,645.4%   
Interest Rs m1,97473 2,707.3%   
Profit before tax Rs m21,7826,599 330.1%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3122,309 273.4%   
Profit after tax Rs m14,9954,291 349.5%  
Gross profit margin %19.227.4 70.0%  
Effective tax rate %29.035.0 82.8%   
Net profit margin %9.020.6 43.6%  
BALANCE SHEET DATA
Current assets Rs m117,03827,167 430.8%   
Current liabilities Rs m43,9318,917 492.7%   
Net working cap to sales %43.887.7 49.9%  
Current ratio x2.73.0 87.4%  
Inventory Days Days9668 141.2%  
Debtors Days Days8530 282.6%  
Net fixed assets Rs m107,4248,862 1,212.2%   
Share capital Rs m1,613458 352.5%   
"Free" reserves Rs m156,01829,656 526.1%   
Net worth Rs m157,63030,113 523.5%   
Long term debt Rs m23,69325 94,771.2%   
Total assets Rs m236,62639,400 600.6%  
Interest coverage x12.091.5 13.2%   
Debt to equity ratio x0.20 18,104.9%  
Sales to assets ratio x0.70.5 133.5%   
Return on assets %7.211.1 64.8%  
Return on equity %9.514.2 66.8%  
Return on capital %12.822.1 58.0%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,036428 13,083.4%   
Fx outflow Rs m6,764786 860.1%   
Net fx Rs m49,272-358 -13,759.3%   
CASH FLOW
From Operations Rs m30,685978 3,137.2%  
From Investments Rs m1,040351 296.2%  
From Financial Activity Rs m-29,488-1,099 2,684.4%  
Net Cashflow Rs m2,340231 1,014.0%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 63.9 32.6%  
Indian inst/Mut Fund % 12.2 7.5 162.7%  
FIIs % 23.7 4.9 483.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 23.7 110.5%  
Shareholders   161,166 85,207 189.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 26, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS